D H van Raalte
Overview
Explore the profile of D H van Raalte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
598
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zwart K, Velthuis S, Polyukhovych Y, Mosterd A, Smidt L, Serne E, et al.
Neth Heart J
. 2021 Jun;
29(10):490-499.
PMID: 34132981
Sodium-glucose cotransporter 2 (SGLT2) inhibitors include a relatively new class of glucose-lowering drugs that reduce plasma glucose concentrations by inhibiting proximal tubular reabsorption of glucose in the kidney, while increasing...
2.
Mosterd C, Kanbay M, van den Born B, van Raalte D, Rampanelli E
Best Pract Res Clin Endocrinol Metab
. 2021 Feb;
35(3):101484.
PMID: 33546983
Diabetic kidney disease (DKD) represents a growing public health burden and is the leading cause of end-stage kidney diseases. In recent years, host-gut microbiota interactions have emerged as an integral...
3.
van Bommel E, Herrema H, Davids M, Kramer M, Nieuwdorp M, van Raalte D
Diabetes Metab
. 2019 Dec;
46(2):164-168.
PMID: 31816432
Aims/hypothesis: Patients with type 2 diabetes (T2D) are usually treated with (combinations of) glucose-lowering medication. The effects of these drugs can be influenced by intestinal microbiota and vice versa, as...
4.
Muskiet M, Bunck M, Heine R, Corner A, Yki-Jarvinen H, Eliasson B, et al.
Diabetes Res Clin Pract
. 2019 May;
153:14-22.
PMID: 31078666
Aims: To compare the effects of long-term treatment with the GLP-1RA exenatide twice-daily versus titrated insulin glargine (iGlar) on renal function and albuminuria in type 2 diabetes (T2DM) patients. Methods:...
5.
Pranger I, van Raalte D, Brands M, Muskiet M, Kema I, Serlie M, et al.
Prostaglandins Leukot Essent Fatty Acids
. 2018 May;
132:8-15.
PMID: 29735021
Glucocorticoid treatment decreases liver insulin sensitivity and may modify fatty acid metabolism. We investigated the influence of oral prednisolone on indices for de novo lipogenesis (DNLi), stearoyl-CoA desaturase (SCDi) and...
6.
Brouwer A, Nguyen H, Snoek F, van Raalte D, Beekman A, Moll A, et al.
Acta Psychiatr Scand
. 2017 Sep;
136(6):534-548.
PMID: 28891192
Objective: Light therapy has become an increasingly popular treatment for depression and a range of other neuropsychiatric conditions. Yet, concerns have been raised about the ocular safety of light therapy....
7.
Smits M, Tonneijck L, Muskiet M, Diamant M, Kramer M, Cahen D, et al.
Diabet Med
. 2016 Jun;
34(4):591-592.
PMID: 27278095
No abstract available.
8.
Smits M, Tonneijck L, Muskiet M, Kramer M, Diamant M, Pieters-van den Bos I, et al.
Diabetes Obes Metab
. 2015 Dec;
18(3):281-8.
PMID: 26640129
Aims: To investigate the effect of infusion of the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide on exocrine pancreatic function. Methods: This was a randomized, placebo-controlled, double-blind, crossover study in 12...
9.
Muskiet M, Tonneijck L, Smits M, Kramer M, Diamant M, Joles J, et al.
Diabetes Obes Metab
. 2015 Dec;
18(2):178-85.
PMID: 26636423
Aims: To determine the acute effect of glucagon-like peptide-1 (GLP-1) receptor agonist exenatide and the involvement of nitric oxide (NO) on renal haemodynamics and tubular function, in healthy overweight men....
10.
Smits M, Tonneijck L, Muskiet M, Kramer M, Cahen D, van Raalte D
Diabetes Obes Metab
. 2015 Oct;
18(3):224-35.
PMID: 26500045
The gastrointestinal hormone glucagon-like peptide-1 (GLP-1) lowers postprandial glucose concentrations by regulating pancreatic islet-cell function, with stimulation of glucose-dependent insulin and suppression of glucagon secretion. In addition to endocrine pancreatic...